<DOC>
	<DOCNO>NCT01175148</DOCNO>
	<brief_summary>Atorvastatin prevention acute GVHD</brief_summary>
	<brief_title>Atorvastatin Prophylaxis Acute Graft-versus-host Disease Patients Undergoing Matched Sibling Allogeneic Transplantation</brief_title>
	<detailed_description>This phase II study atorvastatin prophylaxis acute GVHD patient undergo matched-sibling allogeneic HSCT . This study explore two-pronged acute GVHD prophylaxis strategy , consist pre-treating consent sibling donor atorvastatin stem cell collection , follow addition atorvastatin methotrexate/tacrolimus-based GVHD prophylaxis .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>DONOR ELIGIBILITY CRITERIA : 1 . Donors must ≥18 year age , willing/able provide inform consent . 2 . Female donor childbearing potential negative pregnancy test , must breast feeding . 3 . Adequate hepatic function bilirubin , AST ALT &lt; 2.5 x upper limit normal . 4 . Adequate renal function define serum creatinine clearance ≥ 40 % normal calculate CockcroftGault equation . 5 . Adequate cardiac function per institutional guideline . 6 . Donors positive HIV serology eligible . 7 . No clinical evidence uncontrolled active bacterial , viral fungal infection time stem cell mobilization . 8 . Donors must Karnofsky performance score ≥60 . 9 . Donors history intolerance allergic reaction atorvastatin eligible . Hypersensitivity component atorvastatin . 10 . Method stemcell collection sibling donor discretion treat physician . Although anticipated majority sibling donor undergo GCSF induce stem cell mobilization ; however donor undergo bone marrow harvest stem cell mobilization experimental agent ( e.g . plerixafor ) remain eligible study . PATIENT ELIGIBILITY CRITERIA : 1 . Patients history hematological malignancy bone marrow failure syndrome suitable match sibling allogeneic stem cell transplantation opinion treat transplant physician . 2 . Patients aged 1875 year age eligible . Patients age &gt; 18 ≤ 50 year eligible myeloablative conditioning ( MAC ) , patient &gt; 50 year age , previous history autologous transplantation , high hematopoietic cell transplant comorbidity index ( HCTCI ) score ( &gt; 2 ) , baseline diagnosis hodgkin 's lymphoma , chronic lymphocytic leukemia follicular lymphoma suitable reduce intensity conditioning ( RIC ) transplantation ( however intensity condition regimen remain discretion treat physician ) . 3 . All patient must least one suitable HLAmatched sibling donor accord transplant center 's guideline ( selection appropriate sibling donor ) . 4 . Patient must provide informed consent . 5 . Left ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmia uncontrolled New York Heart Association class IIIIV heart failure . 6 . Bilirubin &lt; 2mg/dl AST ALT &lt; 3 x normal ; absence hepatic cirrhosis . 7 . Adequate renal function define serum creatinine clearance ≥ 40 % normal calculate CockcroftGault equation . 8 . DLCO ( diffusion capacity ; correct hemoglobin ) ≥ 50 % predict . 9 . Karnofsky performance status &gt; 70 . 10 . A negative pregnancy test require woman child bear potential . Breast feeding permit . 11 . Patients positive HIV serology eligible . 12 . No evidence active uncontrolled bacterial , viral fungal infection time transplant conditioning . 13 . Patients history intolerance allergic reaction atorvastatin eligible . 14 . Patients previously take atorvastatin statin drug eligible long contraindication switch atorvastatin ( 40mg/day ) opinion treat physician . 15 . Patients undergo Tcell deplete allogeneic transplantation eligible . 16 . Patients receive condition regimen contain antithymocyte globulin , and/or campath eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HSCT</keyword>
	<keyword>HPC</keyword>
	<keyword>HCT</keyword>
	<keyword>BMT</keyword>
	<keyword>lipitor</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>HMG-CoA Reductase Inhibitor</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
	<keyword>allogeneic transplant</keyword>
	<keyword>GVHD</keyword>
	<keyword>graft-versus-host-disease</keyword>
	<keyword>Graft v Host Disease</keyword>
</DOC>